AR057849A1 - Dialurrea para el tratamiento de hipertension pulmonar - Google Patents
Dialurrea para el tratamiento de hipertension pulmonarInfo
- Publication number
- AR057849A1 AR057849A1 ARP060104767A ARP060104767A AR057849A1 AR 057849 A1 AR057849 A1 AR 057849A1 AR P060104767 A ARP060104767 A AR P060104767A AR P060104767 A ARP060104767 A AR P060104767A AR 057849 A1 AR057849 A1 AR 057849A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- treatment
- combination
- pulmonary hypertension
- Prior art date
Links
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- -1 4-chloro-3-trifluoromethylphenyl Chemical group 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 229940122858 Elastase inhibitor Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 239000003524 antilipemic agent Substances 0.000 abstract 1
- 230000004872 arterial blood pressure Effects 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 229940097217 cardiac glycoside Drugs 0.000 abstract 1
- 239000002368 cardiac glycoside Substances 0.000 abstract 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 229940030606 diuretics Drugs 0.000 abstract 1
- 239000003602 elastase inhibitor Substances 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003815 prostacyclins Chemical class 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229930002534 steroid glycoside Natural products 0.000 abstract 1
- 150000008143 steroidal glycosides Chemical class 0.000 abstract 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 abstract 1
- 229940124549 vasodilator Drugs 0.000 abstract 1
- 239000003071 vasodilator agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05024509 | 2005-11-10 | ||
| EP05027450 | 2005-12-15 | ||
| EP06012234 | 2006-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057849A1 true AR057849A1 (es) | 2007-12-19 |
Family
ID=37622057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104767A AR057849A1 (es) | 2005-11-10 | 2006-10-31 | Dialurrea para el tratamiento de hipertension pulmonar |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100035888A1 (https=) |
| EP (1) | EP1948170A1 (https=) |
| JP (1) | JP5084736B2 (https=) |
| KR (1) | KR20080067000A (https=) |
| AR (1) | AR057849A1 (https=) |
| AU (1) | AU2006312714A1 (https=) |
| BR (1) | BRPI0618522A2 (https=) |
| CA (1) | CA2628849A1 (https=) |
| CR (1) | CR9953A (https=) |
| EC (1) | ECSP088430A (https=) |
| GT (1) | GT200800058A (https=) |
| IL (1) | IL191178A0 (https=) |
| NO (1) | NO20082498L (https=) |
| PE (1) | PE20070806A1 (https=) |
| SV (1) | SV2009002900A (https=) |
| TW (1) | TW200733961A (https=) |
| UY (1) | UY29903A1 (https=) |
| WO (1) | WO2007054216A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE538794T1 (de) * | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| DE202004021759U1 (de) * | 2003-02-21 | 2010-10-07 | ResMed Ltd., Bella Vista | Nasale Anordnung |
| US7557129B2 (en) * | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| WO2004113274A2 (en) * | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| KR101381454B1 (ko) * | 2004-09-29 | 2014-04-04 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트 |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| JP5885012B2 (ja) * | 2007-01-19 | 2016-03-15 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ | Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置 |
| JP2011525503A (ja) * | 2008-06-25 | 2011-09-22 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 心不全を処置するためのジアリールウレア |
| CA2796744A1 (en) * | 2010-04-17 | 2011-10-20 | Bayer Healthcare Llc | Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| MA34553B1 (fr) | 2010-10-01 | 2013-09-02 | Bayer Ip Gmbh | Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué |
| US20140127295A1 (en) * | 2011-03-14 | 2014-05-08 | Cellworks Group, Inc | Compositions, process of preparation of said compositions and method of treating inflammatory diseases |
| US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04007832A (es) * | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| WO2003084543A1 (en) * | 2002-04-10 | 2003-10-16 | Virginia Commonwealth University | Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer |
| WO2004113274A2 (en) * | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| EA010485B1 (ru) * | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| WO2006091542A2 (en) * | 2005-02-22 | 2006-08-31 | Cedars-Sinai Medical Center | Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier |
-
2006
- 2006-10-30 CA CA002628849A patent/CA2628849A1/en not_active Abandoned
- 2006-10-30 EP EP06818314A patent/EP1948170A1/en not_active Withdrawn
- 2006-10-30 KR KR1020087013800A patent/KR20080067000A/ko not_active Withdrawn
- 2006-10-30 JP JP2008539299A patent/JP5084736B2/ja not_active Expired - Fee Related
- 2006-10-30 WO PCT/EP2006/010406 patent/WO2007054216A1/en not_active Ceased
- 2006-10-30 US US12/084,662 patent/US20100035888A1/en not_active Abandoned
- 2006-10-30 AU AU2006312714A patent/AU2006312714A1/en not_active Abandoned
- 2006-10-30 BR BRPI0618522-3A patent/BRPI0618522A2/pt not_active IP Right Cessation
- 2006-10-31 AR ARP060104767A patent/AR057849A1/es not_active Application Discontinuation
- 2006-11-07 UY UY29903A patent/UY29903A1/es not_active Application Discontinuation
- 2006-11-09 TW TW095141431A patent/TW200733961A/zh unknown
- 2006-11-09 PE PE2006001406A patent/PE20070806A1/es not_active Application Discontinuation
-
2008
- 2008-05-01 IL IL191178A patent/IL191178A0/en unknown
- 2008-05-06 CR CR9953A patent/CR9953A/es not_active Application Discontinuation
- 2008-05-06 GT GT200800058A patent/GT200800058A/es unknown
- 2008-05-06 SV SV2008002900A patent/SV2009002900A/es not_active Application Discontinuation
- 2008-05-07 EC EC2008008430A patent/ECSP088430A/es unknown
- 2008-06-04 NO NO20082498A patent/NO20082498L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GT200800058A (es) | 2010-02-23 |
| JP5084736B2 (ja) | 2012-11-28 |
| KR20080067000A (ko) | 2008-07-17 |
| CR9953A (es) | 2008-10-08 |
| UY29903A1 (es) | 2007-06-29 |
| AU2006312714A1 (en) | 2007-05-18 |
| US20100035888A1 (en) | 2010-02-11 |
| NO20082498L (no) | 2008-08-07 |
| SV2009002900A (es) | 2009-04-28 |
| IL191178A0 (en) | 2009-08-03 |
| JP2009514910A (ja) | 2009-04-09 |
| ECSP088430A (es) | 2008-07-30 |
| CA2628849A1 (en) | 2007-05-18 |
| BRPI0618522A2 (pt) | 2011-09-06 |
| TW200733961A (en) | 2007-09-16 |
| WO2007054216A1 (en) | 2007-05-18 |
| PE20070806A1 (es) | 2007-09-29 |
| EP1948170A1 (en) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057849A1 (es) | Dialurrea para el tratamiento de hipertension pulmonar | |
| DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
| CL2023000196A1 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
| PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| BRPI0513433A (pt) | derivados de hidantoìna para o tratamento de distúrbios inflamatórios | |
| AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| ECSP034603A (es) | Combinaciones sinergicas que comprenden un inhibidor de renina para enfermedades cardiovasculares | |
| UY31084A1 (es) | Compuestos de azaindol para la inhibicion de b-secretasa | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| HRP20050663A2 (en) | Malonamide derivatives as gamma-secretase inhibitors | |
| BRPI0612072A2 (pt) | inibidores da aspartil protease | |
| EP2620145A3 (en) | 2,5-dihydroxybenzene compounds for the treatment of of cancer of an organ | |
| AR068947A1 (es) | Inhibidor de la proteina activadora de la 5- lipoxigenasa (flap), composiciones farmaceuticas, sales y solvatos | |
| PE20151666A1 (es) | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep | |
| ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
| AR119318A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
| NO20091254L (no) | Terapeutiske sammensetninger | |
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| ECSP055745A (es) | Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona | |
| JP2009514910A5 (https=) | ||
| CL2021002098A1 (es) | Inhibidor de la quinasa atr para usar en el tratamiento de una enfermedad hiperproliferativa. | |
| AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| ECSP067044A (es) | Compuestos para el tratamiento de trastornos inflamatorios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |